ارتباط با ما
با ما تماس بگیرید
0086-21-58386256
0086-21-58386256
Purpose The long-term follow-up results of patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid and chemotherapy show high cure rates. Several studies have shown high efficacy of single-agent arsenic xide in newly diagnosed APL. However, long-term follow-up results are needed. Patients and Methods …Web
Arsenic xide (As 2 O 3) is a highly effective treatment for patients with relapsed acute promyelocytic leukemia (APL); its role as consolidation treatment for …Web
All-trans retinoic acid (ATRA) plus arsenic xide was found to be noninferior to ATRA plus chemotherapy, and less toxic, in the treatment …Web
Q-T prolongation is a well known and expected effect of arsenic xide treatment. To date, only 3 cases of Q-T prolongation above 500 millisecond (ms) have been reported. No deaths due to cardiac arrhythmias have been attributed to Trisenox. In a detailed independent review of 1000 electrocardiograms from 99 patients on clinical …Web
Figure 1 Synergy between arsenic xide (ATO) and bortezomib in the treatment of acute promyelocytic leukemia. 1. ... Bastie J-N, Balitrand N, Guillemot I, Chomienne C, Delva L. Cooperative action of 1α,25-dihydroxyvitamin D3 and retinoic acid in NB4 acute promyelocytic leukemia cell differentiation is transcriptionally controlled. …Web
PURPOSE. Arsenic combined with all-trans retinoic acid (ATRA) is the standard of care for adult acute promyelocytic leukemia (APL). However, the safety and …Web
This pilot clinical trial studies how well arsenic xide and itraconazole work in treating patients with basal cell cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. ... - Performance status Eastern Cooperative Oncology Group (ECOG) 0 to 2 - Absolute neutrophil count >= 1,500/mcL ...Web
Arsenic xide (ATO) has proved to be even more effective than ATRA as a single agent, and is now routinely used for the treatment of the 20%–30% of patients …Web
Purpose We previously reported our results with a single-agent arsenic xide (ATO) –based regimen in newly diagnosed cases of acute promyelocytic leukemia (APL). The concern remained about the long-term outcome of this well-tolerated regimen. We report our long-term follow-up data on the same cohort. Patients and Methods From …Web
Arsenic xide (As 2 O 3) was approved for treatment of patients with relapsed APL, as it effectively induces CR in the majority of these patients. 15-17 The current study was designed to test the hypothesis that the early addition of arsenic xide as postremission therapy would improve the event-free survival (EFS) of patients with APL …Web
This new model, with greater emphasis on PML–RARα degradation than on transcriptional activation, explains why full PML–RARα degradation, through the cooperative action of arsenic xide ...Web
Purpose This randomized, multicenter, phase III noninferiority trial was designed to test the efficacy and safety of an oral tetra-arsenic tetra-sulfide (As4S4) –containing formula named the Realgar-Indigo naturalis formula (RIF) compared with intravenous arsenic xide (ATO) as both induction and maintenance therapies for …Web
Through participation in a government-sponsored multi-year study, researchers at the Comprehensive Cancer Center at Wake Forest University have helped confirm that arsenic xide – marketed as Trisenox® – significantly improves patient survival when coupled with standard chemotherapy treatment in newly diagnosed patients with acute …Web
Upfront arsenic xide (ATO) and all-trans retinoic acid (ATRA) combination has been proven to be highly effective in acute promyelocytic leukemia (APL) and has become standard therapy in ...Web
As a result, glucose carbon is completely away from mitochondria, and glutamine is essential to maintain TCA cycle activity, which made c-Myc-transformed cells susceptible to inhibition of mitochondrial electron transport chain[36,39], which might explain cooperative effects of 10058F4 with arsenic xide, because arsenic xide is a ...Web
Patients ≥15 years old were randomized to addition of arsenic xide (ATO) consolidation. All patients were randomized to ATRA maintenance with versus without oral chemotherapy. Results. The estimated 5-year overall survival (OS) rate was 82%, and the event-free survival (EFS) rate was 54%. Seven patients (8.4%) died during induction due …Web
Model for the mechanism of Arsenic xide in APL therapy. Arsenic xide binds to cysteine residues on the PML moiety of PML-RARA, triggering the binding of ubiquitin-conjugating enzyme 9 (UBC9) to the PML RING finger domain. ... Non-silent mutations may provide a cooperative effect with the PML-RARA fusion in disease …Web
The use of all-trans retinoic acid (ATRA) and arsenic xide (ATRA/arsenic xide) for the treatment of acute promyelocytic …Web
Colon cancer is the third leading cause of cancer-related deaths worldwide. Recent studies in our laboratory have demonstrated that arsenic xide is cytotoxic in human colon cancer (HT-29), lung (A549) and breast (MCF-7) carcinoma cells. The purpose of the present study is to investigate the effects of arsenic xide on DNA synthesis …Web
However, AML with RARG rearrangement is insensitive to alltrans retinoic acid (ATRA) and arsenic xide (ATO) and carries a poor prognosis. We initiated a global cooperative study to define the clinicopathological features, genomic and transcriptomic landscape, and outcomes of AML with RARG rearrangements collected from 29 study …Web
Here, we propose a potential combination for HCC treatment named arsenic xide cooperate cryptotanshinone (ACCS). A remarkable synergistic therapeutic effect has been achieved compared with drugs alone in both in vivo and in vitro experiments.Web
Abstract. Arsenic xide inhibits growth and promotes apoptosis in many different cancer cell lines. The National Cancer Institute is working cooperatively wiWeb
Abstract. Recent clinical data shows that arsenic xide (As2O3) causes remission in patients with acute promyelocytic leukemia and multiple myeloma without severe side effects. Laboratory data suggest that As2O3 induces apoptosis or cell differentiation of hematopoietic or solid tumor cells. To date, there has been no study on …Web
The application of all-trans retinoic acid (ATRA) and arsenic xide (ATO) has revolutionized the treatment of acute promyelocytic leukemia (APL). More than 80–90% of patients are expected to be cured with a combination of ATRA, ATO and/or chemotherapy. ... (32%) and gastrointestinal bleeding (3%). Similarly, other large cooperative group ...Web
Arsenic xide is an old drug that has recently re- introduced into new medicine. It is very potent against a specific type of leukemic cells harboring translocation between chromosomes 15 and 17. It has been demonstrated that this drug is effective against all stages of acute promyelocytic leukemia, including for remission induction of ...Web
Arsenic xide and all-trans retinoic acid have become the frontline treatments for patients with acute promyelocytic leukemia …Web
Introduction. Arsenic is a naturally occurring element in the earth's crust and is distributed throughout the environment by water. In addition, arsenic compounds are used for treatment of human disease as well as in agricultural applications, such as insecticides, fertilizers, and fungicides. 1 The first time arsenic xide was used in …Web
Chemotherapy, all-trans retinoic acid (ATRA), and arsenic are effective options for acute promyelocytic leukemia (APL). We conducted a 20-year retrospective analysis of newly diagnosed (ND) APL patients treated with arsenic, ATRA and mitoxantrone. After achieving complete remission (CR), patients received 3–5 cycles of …Web
Abstract. Arsenic xide has shown substantial efficacy in treating both newly diagnosed and relapsedpatients with acute promyelocytic leukemia (APL). As a single agent, it induces complete remissions, causing few adverse effects and only minimal myelosuppression. These successes have prompted investigations to elucidate the …Web
Arsenic xide (As 2 O 3) was approved for treatment of patients with relapsed APL, ... for C9710 required a clinical diagnosis of APL with subsequent confirmation of PML-RARα by RT-PCR assay at 1 of 3 cooperative group central laboratories, and written informed consent. Because of the urgency of therapy in patients …Web
The optimal treatments for relapsed acute promyelocytic leukemia (APL) remain equivocal. We conducted a phase 2 study to evaluate the efficacy and feasibility of a sequential treatment consisting of induction and consolidation with arsenic xide (ATO), peripheral blood stem cell (PBSC) harvest after high-dose cytarabine chemotherapy, and …Web
Arsenic, as a traditional Chinese medicine, has a long history of more than 2000 years in China. Arsenic xide (ATO), as a chemotherapeutic drug, has been approved for use in relapsed and refractory acute promyelocytic leukemia by the Food and Drug Administration [].In addition to leukemia, arsenic is also used in solid tumors, …Web
Phase 2 study of arsenic xide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia | Blood | American Society of …Web
Arsenic since ancient times. Widely distributed in nature, arsenic is usually found associated with the ores of antimony and silver, as the sulphides realgar and orpiment, the xide, and as a constituent of many metallic sulphides. The xide ('white arsenic') is a by-product from the roasting of the ores of copper, lead and other metals …Web
